VBI Vaccines To Present New Interim Phase 2b Data From VBI-1901 In Recurrent Glioblastoma Patients In Poster Presentation At 2024 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines Inc. (NASDAQ:VBIV) announced that new interim data from its Phase 2b study of VBI-1901 in recurrent glioblastoma patients will be presented at the 2024 ASCO Annual Meeting. The presentation will include updated and new patient data.
May 22, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VBI Vaccines Inc. will present new interim data from its Phase 2b study of VBI-1901 in recurrent glioblastoma at the 2024 ASCO Annual Meeting. This could generate positive investor sentiment.
The presentation of new interim data at a prestigious conference like ASCO can boost investor confidence and potentially lead to a short-term increase in stock price due to the positive sentiment around the progress of VBI-1901.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100